EGFR and bone metastasis: When conducted the comparison of demographic and clinical characteristics between EGFR-TKI group and EGFR-TKI plus thymosin group, we found that brain metastasis, bone metastasis and first- or second-line EGFR-TKI treatment in two groups had significantly differences, then propensity score matching analysis was applied at a ratio of 2:1.